Struggling Idera Pharmaceutical Inc. (Nasdaq: IDRA) says it raised enough money in a recent public offering to make it through the fourth quarter. The  Cambridge, Mass.-based developer of treatments for psoriasis and lupus reported in a May 15 filing with the U.S. Securities and Exchange Commission that a review of its 2012 financial statements caused accounting firm Ernst & Young LLP to raise “substantial doubt” about the company’s ability to continue as a growing concern, or without the thread of liquidation.

Ernst & Young raised the doubt because of Idera’s history of recurring losses and negative cash flows from operations. The accounting firm cautioned that in order for Idera to remain in business, it would need to raise more capital or obtain an alternate means of financial support.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.